Given the interest in the emerging and evolving coronavirus (COVID-19) pandemic and the questions regarding how this will impact patients with atopic dermatitis (AD) or alopecia who are treated with or without systemic immunomodulating medication, we have created a number of secure, online, de-identified Personal Health Identifier (PHI) – free reporting registries and an anonymous patient reported survey.

We encourage clinicians worldwide to report ALL cases of COVID-19 in their alopecia and atopic dermatitis patients treated with or without systemic immunomodulating medication, regardless of severity (including asymptomatic patients detected through public health screening). Please follow the links below to register by clicking on either of the physician entered registry logos.

If you are a patient with atopic dermatitis  and have developed COVID-19 we encourage you to complete the anonymous survey by clicking on the green SECURE-AD Patients survey logo.

Thank you in advance for your participation.

We encourage clinicians worldwide to report ALL cases of COVID-19 in their alopecia patients treated with systemic immunomodulating medication, regardless of severity (including asymptomatic patients detected through public health screening).
We encourage clinicians worldwide to report ALL cases of COVID-19 in their AD patients, treated with or without systemic immunomodulating medication, regardless of severity (including asymptomatic patients detected through public health screening).
The SECURE-AD Patient survey allows patients with atopic dermatitis (atopic eczema) who have developed COVID-19 to report their experience. This will help us better understand how COVID-19 affects these people and how to improve their care.

We are using cookies on our website

Please confirm, if you accept our tracking cookies. You can also decline the tracking, so you can continue to visit our website without any data sent to third party services.